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Abstract
Magnesium sulfate is the anticonvulsant of choice for eclampsia prophylaxis and treatment; however, the recommended dosing regimens are costly and
cumbersome and can be administered only by skilled health professionals. The objectives of this study were to develop a robust exposure-response
model for the relationship between serum magnesium exposure and eclampsia using data from large studies of women with preeclampsia who
received magnesium sulfate, and to predict eclampsia probabilities for standard and alternative (shorter treatment duration and/or fewer intramuscular
injections) regimens. Exposure-response modeling and simulation were applied to existing data. A total of 10 280 women with preeclampsia who
received magnesium sulfate or placebo were evaluated. An existing population pharmacokinetic model was used to estimate individual serum
magnesium exposure.Logistic regression was applied to quantify the serummagnesium area under the curve-eclampsia rate relationship.Our exposure-
response model-estimated eclampsia rates were comparable to observed rates. Several alternative regimens predicted magnesium peak concentration
< 3.5 mmol/L (empiric safety threshold) and eclampsia rate 0.7% (observed response threshold), including 4 g intravenously plus 10 g intramuscularly
followed by either 8 g intramuscularly every 6 hours × 3 doses or 10 g intramuscularly every 8 hours × 2 doses and 10 g intramuscularly every 8 hours
× 3 doses. Several alternative magnesium sulfate regimens with comparable model-predicted efficacy and safety were identified that merit evaluation
in confirmatory clinical trials.
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Magnesium sulfate (MgSO4) is the anticonvulsant of
choice for eclampsia prophylaxis and treatment.1 In-
ternational guidelines recommend 2 MgSO4 regimens
as standard therapy for prevention and treatment of
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eclampsia: the intravenous Zuspan regimen and the
predominantly intramuscular Pritchard regimen.2,3 De-
spite the wide acceptance of MgSO4 as the first-line
treatment for women with preeclampsia and eclampsia,
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coverage in resource-limited settings remains subopti-
mal, partly because the recommended dosing regimens
are costly and cumbersome and can be administered
only by skilled health professionals.
Since 2013, the World Health Organization (WHO)
has embarked on an initiative to determine whether
simpler alternative dosing regimens of MgSO4 can be
identified, with the goal of optimizing access for women
in resource-limited countries.
The objective of this study was to support the
initiative via a population-modeling approach by es-
tablishing a relationship between estimated magnesium
exposure and eclampsia occurrence using a previously
developed population pharmacokinetic model,4 then to
simulate the probability of eclampsia for various dosing
regimens. The optimal alternative dosing regimen(s)
were then evaluated in terms of simulated eclampsia
probability and magnesium exposures.
Methods
This modeling and simulation study was based on
existing data sets, and specific informed consent from
individual women was not required because of the
retrospective study design.
Ethics approval was secured for each of the individ-
ual studies that were included in this analysis.
This was a 2-part research project that used data sets
for women with preeclampsia from Stanford Univer-
sity Hospital, Stanford, California (“Stanford study”)5;
Siriraj and Khon Kaen Hospitals, Thailand (“Thai
study,” Lumbiganon et al, unpublished); and a mul-
ticenter randomized trial in 33 countries (Magpie
Trial).6 The first part of this project focused on the
development of a population pharmacokinetic model
based on serial pharmacokinetic data from the Stanford
study for 92 pregnant women from a preeclampsia
cohort who received intravenous MgSO4 treatment.
A 2-compartment population pharmacokinetic model
was developed, and body weight and serum creati-
nine concentrations were identified to have a signif-
icant impact on magnesium pharmacokinetics (PK).
Model estimated clearance was 3.72 L/h, and distri-
bution volume was 32.4 L/85 kg. The final model
structure and simulated magnesium profiles for stan-
dard and alternative intravenous and intramuscular
regimens are provided in Supplemental Table 1 and
Supplemental Figures 1 and 2 (additional details can
be found in the previous publication).4 The second
part (presented in the current article) consisted of
exposure-response (E-R) modeling using pooled clin-
ical outcome data from the Thai study and the Mag-
pie Trial6 to predict magnesium exposure and the
probability of eclampsia for various MgSO4 dosing
regimens.
For the Magpie Trial, women provided informed
consent prior to participation. Each hospital in the trial
secured appropriate local ethics or research committee
approval before opening to recruitment. In the UK,
the trial was approved by the Northwest Multicentre
ResearchEthics Committee. It was also approved by the
WHO Scientific and Ethical Review Group, Geneva,
Switzerland. All women provided written informed
consent.
The Thai study was approved by the Ethics Commit-
tees of (1)KhonKaenUniversity, February 9, 2015, ref-
erence no. HE581035, (2) Faculty of Medicine, Siriraj
Hospital, Mahidol University, July 3, 2015, reference
no. Si350/2015, and (3) Khon Kaen Hospital, July 15,
2015, reference no. KE57047.
Characteristics of the Studies
Supplemental Table S2 presents a summary of the
characteristics of the 3 studies used to develop the
population PK model4 and the E-R model (current
analysis).
Outline of Analysis
No serum magnesium samples were collected in the
Magpie Trial, and only sparse postdose samples were
collected in the Thai study. Therefore, serum mag-
nesium pharmacokinetic exposure, expressed as area
under the curve (AUC) for change from baseline in
serum magnesium concentration, was estimated using
the pharmacokinetic model.4 Subsequently, the rela-
tionship between the projected AUC and the observed
eclampsia outcome was quantified using a logistic re-
gression approach. Using the developed E-Rmodel, the
probability of eclampsia occurrence was predicted for
different types of “typical” women who received the
standard Zuspan and Pritchard regimens and a series
of simplified alternative intravenous and intramuscular
dosing regimens that were considered more practical
and/or convenient compared with the standard regi-
mens, by virtue of fewer injections, shorter treatment
duration, or lower doses.
Eclampsia Response
Observed eclampsia outcomes from the Magpie Trial
and the Thai study were pooled and included in the
analysis. Of the women included in the analysis, 127 de-
veloped eclampsia: 37 received MgSO4 (36 from the
Magpie Trial with 18 on the intravenous and 18 on the
intramuscular maintenance regimen, respectively, and 1
from the Thai study) and 90 who received placebo (all
from the Magpie Trial). Additional details regarding
the number of women used for the analysis are provided
in Supplemental Table S2.
Pharmacokinetic Exposure
Using the established pharmacokineticmodel,4 individ-
ual AUCs were predicted based on actual dose amount,
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route of administration (intravenous or intramuscular)
and covariates of body weight and serum creatinine.
Individual AUC values for the change from baseline
serum magnesium concentration were calculated using
the clearance (CL) function derived from the popula-
tion pharmacokinetic model according to the following
equations:










AUCi = DO SEI V,iC Li and AUCi =
F · DO SEI M,i
C Li
where Cri is the serum creatinine concentration for
patient i,WTi is the body weight for patient i,DOSEIV,i
is the total intravenous dose for patient i received,
DOSEIM,i is the total intramuscular dose for patient
i received, and F is the absolute bioavailability for
intramuscular dosing, which was estimated as 0.862
based on the published literature.7
Dose Amount
In the Magpie Trial, the start and stop dates of MgSO4
treatment, route of administration, and total dose
administered were recorded. Specific loading andmain-
tenance doses and the timing of MgSO4 administration
were determined from the study protocol. The date of
first eclampsia episode was recorded, but not the time
of occurrence for the majority (92.4%) of the women.
Therefore, the exact amount of MgSO4 administered
at the time of eclampsia occurrence could not be
precisely determined. As a result, the total MgSO4 dose
administered up to the day of first eclampsia was used
in the AUC calculation.
Estimation of AUC
A summary of the baseline characteristics of women
in the analysis population is presented in Supplemental
Table S3. In theMagpie Trial, 2 of the pharmacokinetic
model-identified covariates (maternal weight and serum
creatinine concentration) were not collected but were
assigned the median values of the Stanford study data
set (85 kg and 0.8 mg/dL, respectively). As a result,
the AUC values in the Magpie Trial were informed
only by total dose and route of administration, not
by individualized CL estimates from the population
pharmacokinetic model. For the Thai study, maternal
weight and serum creatinine were available for 383 and
168 women, respectively. Missing values were assigned
the median values in the Thai study of 73 kg (n = 6)
and 0.6 mg/dL (n = 221), respectively.
E-R Model Development
Logistic regression was applied to quantify the serum
magnesium AUC-eclampsia occurrence relationship
according to the following equation:





= b0 + b1 · AUCi
+ bx · covx,i
where pi is the probability of eclampsia occurrence
and logit(p) is the log odds of the probability of
eclampsia occurrence, covx,i is the value of covariate x
for patient i, b0 is the intercept, and b1 and bx are the
coefficients of AUC and covariate x, respectively. Age,
previous use of anticonvulsants (yes/no), and a com-
bined measure of blood pressure and urinary protein
were evaluated as potential covariates. Preeclampsia
severity was treated as a dichotomous variable in the
analysis of the Magpie Trial (severe vs not severe
based on blood pressure, urinary protein, and signs
or symptoms of imminent eclampsia). However, for
the purposes of this analysis, we categorized women
into 3 levels: level 2 was diastolic blood pressure
(BP)  110 mm Hg on 2 occasions or systolic BP 
170 mm Hg on 2 occasions plus  3+ proteinuria;
level 1 was diastolic BP  100 mm Hg on 2 occasions
or systolic BP  150 mm Hg on 2 occasions plus  2+
proteinuria; and level 0 was women who were neither
level 2 nor level 1. These criteria were similar to the
definition of severe preeclampsia in the Magpie Trial,
but signs and symptoms of imminent eclampsia data
were unavailable to replicate the exact definition used
in the Magpie Trial. Antihypertensive use was not
evaluated as a covariate in our analysis, but its use after
trial entry was generally similar between patients who
received MgSO4 and placebo in the Magpie Trial, with
methyldopa, nifedipine, and hydralazine as the antihy-
pertensive agents used most frequently. A piece-wise
logistic regression model was applied for age to also







= b0 + b1 · AUCi + b2 · Agei
+ δ · (Agei − k) · I ((Agei − k ) > 0)
where κ represents a knot point in the slope of age, δ is
the difference in slope before and after the knot point,
and I() is an indicator function that returns a 1 if the
condition is true and returns a 0 otherwise.
Model Simulations
The probability of eclampsia occurrence was predicted
for 27 different types of women with all possible com-
binations of age (20, 30, and 40 years), maternal body
weight (60, 85, and 110 kg), and serum creatinine con-
centrations (0.5, 0.8, and 1.2 mg/dL). The alternative
4 The Journal of Clinical Pharmacology / Vol 00 No 0 2019
regimens were selected (in part) based on the findings
of an international survey on clinical practice patterns
of MgSO4 or their previous application in research
contexts for eclampsia prophylaxis, tocolysis, or fetal
neuroprotection and were prespecified by the study au-
thors prior to the simulation analysis.8,9 Supplemental
Table S4 describes the features of each regimen.
Analysis Software
Analysis data-set creationwas done in SAS (version 9.4l
SAS Institute Inc., Cary, North Carolina). E-R model
development, simulations and plotting were performed
in R (version 3.5.1; The R Project for Statistical Com-
puting [www.r-project.org]).
Results
Individual Serum Magnesium AUC Estimates
For the Magpie Trial, the median AUC estimates
were 769 mg·h/L (geometric mean, 706 mg·h/L) and
906 mg·h/L (geometric mean, 775 L·h) for the in-
travenous and intramuscular dosing regimens, respec-
tively. Because of the imputation of values for missing
body weight and serum creatinine, the AUC values for
this study were solely derived from individual dosing
information; hence, AUC distribution was relatively
narrow. Using lower imputed values for body weight
and serum creatinine (80 kg and 0.7 mg/dL, respec-
tively), resulted in an AUC that was approximately
5% lower, which suggested that the AUC values were
relatively insensitive to small deviations in body weight
and serum creatinine from the median values derived
from the Stanford study. For the Thai study, the median
AUC was higher (1351 mg·h/L, geometric mean =
1278 mg·h/L) with a wider distribution, which was
consistent with infusion durations longer than 24 hours,
maintenance doses higher than 1 g/h, and CL values
that could be individualized for each woman using
body weight and serum creatinine concentrations. The
frequency distributions for estimated AUC values for
the Magpie Trial and the Thai study are presented in
Supplemental Figure S3.
Eclampsia Occurrence
Most of the eclampsia seizures occurred on the first
day of treatment with MgSO4. The distribution of
onset day of eclampsia is presented in Supplemental
Figure S4.
Exposure-Response Model Results
An overview of the E-R model development is sum-
marized in Supplemental Table S5. Level of blood
pressure/urinary protein and anticonvulsant drug use
before MgSO4 treatment did not show a significant
relationship with eclampsia, but age and AUC demon-
strated a clear relationship. There was no collinearity
observed between these 2 covariates, and there was also
no statistically significant interaction betweenAUCand
age when tested during model building, confirming that
they independently contributed to the E-R model. The
final logistic E-R model included a piece-wise linear
age effect with a knot point at 22 years. The AIC
(Akaike Information Criterion) score of the final model
dropped 24 points compared with the E-R model with
age included as a linear covariate.
Age  22 years: Logit(P) = −6.29 – 0.00164 • AUC +
0.154 • age
Age > 22 years: Logit(P) = −4.72 – 0.00164 • AUC +
0.010 • age
Figure 1 illustrates an overlay of the observed
and model-predicted eclampsia rates as a function of
magnesium AUC and age. Predicted eclampsia rates
reasonably matched the observed rates for each of
the age and AUC groups (segmented into quantiles),
except for the AUC group of women with the lowest
magnesium exposure (0-371 mg·h/L), where the model
underpredicted the observed eclampsia rate. All women
in this lowest quantile had treatment duration that
was less than 12 hours, and 8 of 13 (61.5%) had their
first seizure within the first 20 minutes. Removal of
these women from the analysis resulted in an observed
eclampsia rate of 1.6% in this AUC quantile, which
was more consistent with the observed rate. In total,
37 women treated with MgSO4 had eclampsia, 21 of
whom (56.8%) were22 years old. In the placebo arm,
90 women had eclampsia, of whom 53 (58.9%) were
22 years old.
Using the final E-R model, overall mean eclampsia
rates were predicted for each regimen for 27 different
types of women, as previously defined. Table 1 presents
the estimated magnesium Cmax and predicted mean
overall eclampsia rates, for both all women and women
older than age 22 years. Supplemental Figure S5 and
Figure S6 graphically depict the simulated eclamp-
sia rates for each of these types of women for all
the intravenous- and intramuscular-based regimens,
respectively.
Criteria for evaluating the safety and efficacy of
these regimens included a predicted range of mag-
nesium Cmax values that did not exceed the reported
safety margin of 3.5 mmol/L10,11 and an overall mean
predicted eclampsia rate  0.7% (the overall observed
eclampsia rate in all MgSO4-treated women in the
Magpie and Thai studies [37 of 5290]).
As shown in Table 1, all alternative regimens had
predicted eclampsia rates that were lower compared
with placebo for all women and for women older
than 22 years. The intravenous regimens with higher
maintenance doses of 2 g/h for 24 hours (either with
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Figure 1. Observed and E-R model-predicted eclampsia rate versus estimated AUC (left) and age (right).AUC, area under the curve; E-R, exposure-
response. Horizontal lines: parameter ranges in each quantile; AUC quantiles: 0 (placebo), 0-371 mg·h/L (less than half of a standard dose), 371-
757 mg·h/L (less than a standard dose), 757-848 mg·h/L (equivalent to a standard intravenoous dose, 28 g), and >848 mg·h/L (equivalent to a standard
intramuscular dose, 39 g and higher dose). Age quantiles: < 22, 22-26, 27-31, >31 years. Solid dot and vertical line: mean and 95%CI of observed
eclampsia rate for each quantile. Solid squares: model-predicted eclampsia rate for each quantile.
the same loading dose as the standard regimen or with
a higher loading dose of 6 g), and the intravenous
regimen with both a higher loading dose (12 g) and
a higher maintenance dose of 3 g/h for 12 hours met
the efficacy criterion, but the estimated Cmax for these
regimens exceeded the safety criteria. Of the alternative
intravenous regimens, only the 8-g intravenous loading
dose over 60 minutes followed by 2 g/h for a 10-hour
regimen nearly met the selection criteria, with the same
mean eclampsia rate as the standard Zuspan regimen,
but the upper range of predicted Cmax for this regimen
was 3.55 mmol/L, just above the safety criteria. Of
the alternative intramuscular maintenance regimens
evaluated, all met the safety criteria. Two regimens
using the same loading dose as the Pritchard
regimen (but with fewer maintenance intramuscular
injections) met the efficacy criterion: 4 g intravenous/
10 g intramuscular loading dose followed by 8 g every
6 hours × 3 doses or 10 g every 8 hours × 2 doses. In
addition, 1 regimen without an intravenous loading
dose (10 g intramuscularly every 8 hours× 3 doses) also
met the efficacy criterion, with a mean eclampsia rate
of 0.70%. Although the other intramuscular regimen
without intravenous loading (10 g intramuscularly
every 12 hours × 2 doses) did not meet the efficacy
criterion, it had a predicted eclampsia rate that was




Our E-R model generally performed well, enabling
simulations of eclampsia rates that we used to sys-
tematically assess various dosing regimens and identify
promising alternative regimens prior to conducting
large comparative clinical trials.12
Results
We identified several promising alternative regimens
that were predicted to perform as well as the standard
Zuspan or Pritchard regimens. Currently, there are
limited published data for these alternatives. To our best
knowledge, this was the first to apply PKPD modeling
to estimate the relationship between magnesium sulfate
exposure and eclampsia prevention.
Clinical Implications
Some of the alternative regimens require careful con-
sideration of differences in the context in which women
with preeclampsia are treated globally. For instance, the
regimen of 8 g intravenously over 60 minutes followed
by a continuous infusion of 2 g/h for 10 hours would
remain challenging in low-resource settings, in which
safe intravenous administration (eg, with a controlled
infusion pump) is still limited to high-level facilities.
Administration of the same total dose (28 g) for shorter
treatment duration when compared with the standard
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(h) Min-Maxa All Ages Age > 22 Years
Placebo (IV/IM combined) 0 — 0 2.1 1.2
4 g in 20 min, 1 g/h × 24 h
Standard regimen (Zuspan)
28 24.3 1.47–2.47 0.64 0.37
4 g in 20 min, 2 g/h × 24 h 52 24.3 1.96–4.12 0.25 0.15
6 g in 20 min, 2 g/h × 24 h 54 24.3 1.97–4.16 0.24 0.14
12 g in 120 min 3 g/h × 12 h 48 14.0 2.43–5.15 0.29 0.17
12 g in 120 min 2 g/h × 8 h 28 10.0 2.27–3.79 0.64 0.37
8 g in 60 min, 2 g/h × 10 h 28 11.0 2.01–3.55 0.64 0.37
4 g in 20 min, 1 g/h × 12 h 16 12.3 1.47–2.22 1.0 0.61
4 g in 20 min, 1 g/h × 8 h 12 8.3 1.47–2.11 1.2 0.73










Injections) Min-Maxa All Ages Age > 22 Years
Placebo (IV/IM combined) 0 – 0 2.1 1.2
4 g IV/10 g IM, 5 g Q 4 h × 5
Standard regimen (Pritchard)
39 20.3 (6) 1.65–2.73 0.50 0.29
4 g IV/10 g IM, 8 g Q 6 h × 3 38 18.3 (4) 1.65–2.88 0.52 0.30
4 g IV/10 g IM, 10 g Q 8 h × 2 34 16.3 (3) 1.65–2.82 0.59 0.35
4 g IV/10 g IM, 5 g Q 4 h × 2 24 20.3 (3) 1.65–2.54 0.84 0.49
4 g IV/10 g IM 14 0.3 (1) 1.65–2.49 1.2 0.71
10 g IM 10 – (1) 1.25–1.81 1.4 0.84
10 g IM Q 12 h × 2 20 12.0 (2) 1.37–2.22 1.0 0.58
10 g IM Q 8 h × 3 30 24.0 (3) 1.53–2.71 0.70 0.41
4 g IV/6 g IM 10 0.3 (1) 1.48–2.12 1.4 0.82
g, Gram; h, hour; IM , intramuscular; IV, intravenous; Mg , serum magnesium;Q, every.
Dosage form in simulated dosing regimen was MgSO4·7H2O, which contains 10% of magnesium.
aMinimum and maximum predicted Cmax across typical values of body weight (60, 85, 110 kg) and creatinine concentration (0.5, 0.8, 1.2 mg/dL).
bAll ages is mean of 27 types of women with all possible combinations of age (20, 30, and 40 years), maternal body weight (60, 85, and 110 kg), and serum
creatinine concentrations (0.5, 0.8, and 1.2 mg/dL). Age > 22 years is mean of 18 types of women aged 30 and 40 years old with each possible combination of
the same maternal body weights and serum creatinine concentrations.
Zuspan regimen would not reduce drug costs, but the
shorter treatment duration may reduce other health-
care costs associated with administration of intra-
venous MgSO4.13
Promising intramuscular regimens, especially
those without an intravenous loading dose (10 g
intramuscularly every 8 hours × 3 doses), had greater
magnesium concentration fluctuations within the
dosing interval, the clinical consequences of which are
unknown because of lack of consensus for maintaining
a trough concentration above a certain threshold for
eclampsia prophylaxis. Although these alternative
intramuscular-only regimens may overcome some of
the current challenges with standard regimens in low-
resource countries,14 possibly reducing the associated
morbidity and mortality from treatment delays in these
settings, they should be tested in rigorous research
to generate evidence on their clinical comparative
efficacy and safety with the standard regimens. The
knot point of 22 years of age used in our model was
based on the observed data and the model fitting, such
that lower age was associated with a higher risk of
eclampsia. We are not aware of any clinical significance
to the knot point of 22 years in relation to the risk of
eclampsia.
Research Implications
Apart from supporting selection of promising regimens
for use in future randomized trials, the results of our
modeling and simulation study provide an indication of
which MgSO4 regimens may have a higher safety risk
or potential for reduced efficacy, such that their use in
randomized trials would not be recommended. For in-
stance, the alternative regimens using the same loading
dose as the Pritchard regimen with higher maintenance
infusion rates of 2 and 3 g/h were associated with Cmax
values that exceeded the 3.5 mmol/L safety threshold.
Whereas a common regimen, such as 4 g intravenously
followed by 1 g/h for 12 hours may be insufficient to
protect young women with preeclampsia.
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Strengths and Limitations
Our E-R model provided a robust estimation of the
magnesium E-R relationship for eclampsia and pro-
vided a mechanism to systematically assess various
dosing regimens to help identify promising alternatives
prior to conducting large comparative clinical trials.
As the precise relationship between magnesium ex-
posure and efficacy is not well defined, the minimum
effective serum magnesium concentration and the PK
driver for eclampsia prophylaxis are unknown, likely
because of insufficient data for women with preeclamp-
sia progressing to eclampsia to draw reliable conclu-
sions. In the absence of knowledge of the relationship
between PK and efficacy, it was assumed that AUC for
changing from baseline magnesium was the best PK
parameter to correlate with prevention of eclampsia (as
opposed to Cmax or trough concentration, for example)
because a specific PK parameter driver for magne-
sium efficacy is unknown. Our model underestimated
the eclampsia rate for women with the lowest serum
magnesium exposure (AUC 0-371 mg h/L), which may
have been because of the inclusion of women who
experienced eclampsia shortly after starting treatment
(8 of 13 women had eclampsia within 20 minutes of
treatment). There may have been insufficient time for
MgSO4 to penetrate the effect site to have activity.
We were unable to individualize the serum mag-
nesium exposure for the majority of women because
of missing body weight and creatinine concentration.
In addition, the lack of renal function values in the
Magpie Trial and use of the median creatinine con-
centrations from the Stanford Trial could potentially
confound and/or bias the estimated MgSO4 exposure
levels because magnesium is excreted by the kidneys
at a rate proportional to the plasma concentration
and glomerular filtration. However, the magnesium
AUC was relatively insensitive to small deviations in
body weight and serum creatinine. Hence, confidence
intervals of MgSO4 exposure and prediction intervals
of eclampsia rate were not provided because of the lack
of individual exposures, use of median exposure levels
from the Stanford study, and use of absorption rate
constant and absolute bioavailability values from the
literature.7
Conclusions
We developed a robust E-R model to estimate eclamp-
sia outcome following treatment of women with
preeclampsia with MgSO4. Of the intravenous regi-
mens evaluated, an 8-g intravenous loading dose over
60 minutes followed by a continuous infusion of 2 g/h
for 10 hours had the same mean eclampsia rate as
the standard Zuspan regimen, but the upper range of
predicted Cmax included 3.55 mmol/L, just above the
safety criterion used for our analysis. The intramuscular
regimens with the same loading dose as the Pritchard
regimen but fewer maintenance doses (8 g intramuscu-
larly every 6 hours × 3 doses; and 10 g intramuscularly
every 8 hours× 2 doses) appeared to perform as well as
the Pritchard regimen. In addition, 1 regimen without
intravenous loading dose (10 g intramuscularly every
8 hours x 3 doses) also met the efficacy criterion,
with a mean eclampsia rate of 0.70%. Future trials
to investigate the noninferiority of alternative MgSO4
regimens should consider using the most promising
regimens identified in this modeling and simulation
study with due consideration of the clinical context of
MgSO4 use.
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